首页 | 本学科首页   官方微博 | 高级检索  
检索        

Graves病患者治疗前、后血清甲状腺刺激抗体和TSH结合抑制免疫球蛋白活性的观察
引用本文:应峰,刘超,蒋须勤,覃又文,刘翠萍,陈家伟,张忠邦.Graves病患者治疗前、后血清甲状腺刺激抗体和TSH结合抑制免疫球蛋白活性的观察[J].标记免疫分析与临床,1996(1).
作者姓名:应峰  刘超  蒋须勤  覃又文  刘翠萍  陈家伟  张忠邦
作者单位:南京医科大学第一附属医院内分泌科
摘    要:本文研究了Graves病(GD)患者在抗甲状腺药物(ATD)治疗前、后血清甲状腺刺激抗体(TSAb)和TSH结合抑制免疫球蛋白(TBII)的变化,发现治疗前TSAb和TBII的检出率分别为91.7%和79.2%,治疗后两抗体的活性及阳性率均显著下降,表明抗甲状腺药可改善GD患者的免疫异常。TSAb和TBII活性不相关,提示TSH受体抗体(TRAb)具有异质性。TSAb和TBII活性与血清甲状腺激素水平无相关关系,说明体外测定的TSAb或/和TBII活性并不能完全反映甲亢的严重程度。

关 键 词:甲状腺肿.突眼性,甲状腺拮抗剂,自身抗体/甲状腺,抗体.TSH受体

Study of Thyroid Stimulating Antibody and TSH-Binding Inhibition Immunoglobulin in Patients With Graves' Disease Before and After Therapy
Ying Feng,Liu Chao,Jiang Xuqin,et al..Study of Thyroid Stimulating Antibody and TSH-Binding Inhibition Immunoglobulin in Patients With Graves'''' Disease Before and After Therapy[J].Labeled Immunoassays and Clinical Medicine,1996(1).
Authors:Ying Feng  Liu Chao  Jiang Xuqin  
Abstract:Thyroid stimulating antibody (TSAb) and TSH binding inhibition immunoglobulin (TBII) were measured in patients with Graves disease.TSAb and TBII were detected in 91.7%(22/24) and 79.2%(19/24) of patients, respectively before treatment.Both the activities and positivity were significantly reduced after antithyroid drug (ATD)therapy,suggesting that it exerted immunosuppresive effect on the patients. No correlation was found between TSAb and TBII activities,indicating the existence of heterogeneous population of TSH receptor antiboby. TSAb and/or TBII activities might not entirely reflect the severity of hyperthyroidism because of the absence of correlation between the activities and thyroid hormone levels.
Keywords:Goiter  exophthalmic Thyroid antagonists Autoantibodies/thyroid Antibodies  TSH receptor
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号